TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Difference in GAT IOP between positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of AF/AFL/AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety Profile Measured by Grade ≥3 TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of Schirmer's test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of tear meniscus height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of non-invasive tear break-up time (NITBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women who took the abortion pills as instructed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Adherence to Fluid Intake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Adherence to Diet
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Undertriage
Endpoint domain: Adverse events/effects
Primary endpoint: Faecal calprotectin testing completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MyMR website usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional vision improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid Intima-Media Thickness progression/regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean adenoma per procedure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Satisfaction in Intensive Care Unit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in time to exercise induced ST depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean change in tear eosinophil level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in the Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax of OTR Tablet and OXYCONTIN Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of OTR Tablet and OXYCONTIN Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCINF of OTR Tablet and OXYCONTIN Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive, Language and Motor Composite Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometry multiple measures, viz. Weight, length/height and head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-injection glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tumor mutation burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T cell-inflamed gene expression profile (GEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HIV sero-incidence
Endpoint domain: Mortality/survival
Primary endpoint: Total amount of ropivacaine injected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe COVID-19 Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-specific knowledge gained
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Value of Airway Dead Space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels and activity of VWF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of ADAMTS13 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional Capacity: The 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overcorrection of valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average number of detected incidents
Endpoint domain: Adverse events/effects
Primary endpoint: average number of drugs per patient
Endpoint domain: Resource use
Primary endpoint: average of medication changes
Endpoint domain: Resource use
Primary endpoint: average of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: time to perform scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis of pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall adequacy of the scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in interstitial fluid pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of fungi found in lung cancer tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of cases of fungi found in non-lung cancer tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in patient's skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evaluation of skin problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assessment of the scar by the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nightmare frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nightmare Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of stromal cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Celebrex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty syndrome distribution (Fried phenotype)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty syndrome distribution (instrumental activities of daily living)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: LDL - Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL - Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tricuspid regurgitant jet velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Weekly Psychogenic Non-epileptic Seizure-events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of appropriateness of oral anticoagulant prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline organoleptic score of breath (OLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in H2S and CH3SH level in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of change/termination of treatment modality
Endpoint domain: Adverse events/effects
Primary endpoint: Related events for aortic dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Achieving Seroprotection Against Each Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Achieving Seroconversion Against Each Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Serum HAI Against Each Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Pupil Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Gaze Nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Lack of Convergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Pruritus Using ItchRO Weekly Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in ADC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of fetal cytogenetic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of insertion of each device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: D1-specific dopaminergic modulation of prefrontal functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of vessels with detectable blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aggregate mid-band fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectroscopic slope and intercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta of scores of questionnaires on quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delta of scores of questionnaires on cognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Delta of scores of questionnaires on behavioral functions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of procedures before declared unassisted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Abdominal Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DTI Percentage Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Completing EEG
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sputum IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sputum IL-17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Serial erythrocyte methotrexate polyglutamate measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID) at 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Outcomes of Sleep Questionnaire (FOSQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in weekly frequency of moderate to severe VMS from baseline to week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly frequency of moderate to severe VMS from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of moderate to severe VMS from baseline to week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of moderate to severe VMS from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of SARS-CoV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Presence of any adverse effects related to HCQ
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of COVID-19 related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of epithelial and conjunctive zones in the adnexal mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Picking Symptom Assessment Scale (SP-SAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate of Copaxone therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: POPF rate (in %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in sex steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Successful rate in closing PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opiate Overdose Knowledge Scale (OOKS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Passing the Galveston Orientation Amnesia Test (GOAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient between IGFBP-3 and insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of free fatty acids with insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disposition index in subjects with glucose intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating Endothelial microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial blood flow regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting metabolic rate (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal birth weight (gram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ponderal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target engagement by lorcaserin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Absolute Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DPOAE and TEOAE measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inhibition of platelet aggregation (mIPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total clearance of external genital or perianal warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Activity level of Rac1 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Early Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited symptoms during the 7-day follow-up period
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unsolicited symptoms during the 30-day follow-up period
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of grade 3 vaccine related local and general symptoms during the 30-day follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events during the entire study
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and efficacy assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Major Adverse Cardiovascular Events (MACEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Capacity to form neurospheres in vitro
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RNA expression of 5 stem cell markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Capacity to form invasive brain tumor after orthotopic implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Technical and clinical success in performing submucosal endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Horizontal Change in Alveolar Ridge Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the telephone interview post-test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to reach remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skeletal muscle whole muscle membrane fatty acid composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in skeletal muscle sodium pump (Na/K ATPase) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skeletal muscle sarcoplasmic reticulum calcium (SERCA) ATPase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body image evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Achieving Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite event rate of death, nonfatal myocardial infarction, or ischemic-driven Target-Vessel Revascularization
Endpoint domain: Mortality/survival
Primary endpoint: mean difference in post operative pain VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Space Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Grade 3 and 4 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious Adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuations for AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean 24-hour Reflective Total 5 Symptoms Score (T5SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in aortic valve area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decolonization efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: proportion of patients with complete or almost complete relief of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Temperature changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Wearing UV Sensor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Receiving Text Messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Are Able to Discontinue Use of Glucocorticoid without Loss of Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Able to Reduce Use of Glucocorticoid by 50 Percent (%) or More without Loss of Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average and worst pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Diagnosis of placenta accreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Decrease in subretinal fluid thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in sexual activity status
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Prevalence of genital-tract tissue resident memory (TRM) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Square-root Area of Geographic Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Surgical Site Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Regional cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Clearance of All Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported eating behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of visual assessment of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of visual assessment of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of visual assessment of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes